IL148119A0 - Novel spiro compounds - Google Patents

Novel spiro compounds

Info

Publication number
IL148119A0
IL148119A0 IL14811900A IL14811900A IL148119A0 IL 148119 A0 IL148119 A0 IL 148119A0 IL 14811900 A IL14811900 A IL 14811900A IL 14811900 A IL14811900 A IL 14811900A IL 148119 A0 IL148119 A0 IL 148119A0
Authority
IL
Israel
Prior art keywords
spiro compounds
novel spiro
novel
compounds
spiro
Prior art date
Application number
IL14811900A
Other languages
English (en)
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of IL148119A0 publication Critical patent/IL148119A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14811900A 1999-08-20 2000-08-11 Novel spiro compounds IL148119A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23357399 1999-08-20
JP2000137692 2000-05-10
PCT/JP2000/005427 WO2001014376A1 (en) 1999-08-20 2000-08-11 Novel spiro compounds

Publications (1)

Publication Number Publication Date
IL148119A0 true IL148119A0 (en) 2002-09-12

Family

ID=26531087

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14811900A IL148119A0 (en) 1999-08-20 2000-08-11 Novel spiro compounds

Country Status (36)

Country Link
US (3) US6326375B1 (es)
EP (1) EP1204663B1 (es)
KR (1) KR100749713B1 (es)
CN (2) CN100457757C (es)
AR (1) AR029000A1 (es)
AT (1) ATE253064T1 (es)
AU (1) AU767229B2 (es)
BG (1) BG65805B1 (es)
BR (1) BR0013423A (es)
CA (1) CA2379103C (es)
CO (1) CO5200768A1 (es)
CZ (1) CZ2002533A3 (es)
DE (1) DE60006251T2 (es)
DK (1) DK1204663T3 (es)
DZ (1) DZ3175A1 (es)
EA (1) EA004507B1 (es)
EE (1) EE05248B1 (es)
ES (1) ES2206287T3 (es)
GE (1) GEP20053488B (es)
HK (1) HK1043123B (es)
HR (1) HRP20020102B1 (es)
HU (1) HUP0203107A3 (es)
IL (1) IL148119A0 (es)
IS (1) IS2420B (es)
MX (1) MXPA02001693A (es)
MY (1) MY130769A (es)
NO (1) NO323514B1 (es)
NZ (1) NZ517057A (es)
PE (1) PE20010645A1 (es)
PL (1) PL353743A1 (es)
PT (1) PT1204663E (es)
RS (1) RS50484B (es)
SK (1) SK286609B6 (es)
TR (1) TR200200408T2 (es)
TW (1) TWI279402B (es)
WO (1) WO2001014376A1 (es)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US6462053B1 (en) * 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6803372B2 (en) * 1999-08-20 2004-10-12 Banyu Pharmaceutical Co., Ltd. Spiro compounds
EP1337257A4 (en) * 2000-10-03 2004-04-07 Univ California USE OF NEUROPEPTIDE Y ANTAGONISTS IN THE TREATMENT OF ALCOHOLISM
US6566367B2 (en) 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
EP1695977A3 (en) * 2000-12-12 2006-09-20 Neurogen Corporation Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines
CA2432809C (en) 2000-12-21 2010-11-30 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
US6946476B2 (en) 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
US6924291B2 (en) 2001-01-23 2005-08-02 Merck & Co., Inc. Process for making spiro isobenzofuranone compounds
WO2002094825A1 (fr) * 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
EP1470129B1 (en) * 2001-07-24 2009-01-28 Merck & Co., Inc. Radiolabeled neuropeptide y y5 receptor antagonists
US7205417B2 (en) * 2001-08-07 2007-04-17 Banyu Pharmaceutical Co., Ltd. Spiro compounds
AU2002359706A1 (en) * 2001-12-17 2003-06-30 Merck And Co., Inc. Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
JP2005517654A (ja) * 2001-12-17 2005-06-16 メルク　エンド　カムパニー　インコーポレーテッド 日周期リズム障害の治療方法
US6605720B1 (en) 2002-01-28 2003-08-12 Merck & Co., Inc. Process for making spirolactone compounds
EP1496838B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
EP1532147B1 (en) * 2002-06-27 2006-08-02 Schering Corporation Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1601666A2 (en) * 2002-07-02 2005-12-07 Schering Corporation New neuropeptide y y5 receptor antagonists
CA2492225A1 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
US7368569B2 (en) * 2002-10-18 2008-05-06 Merck & Co., Inc. Process for making spirolactone compounds
WO2004050652A1 (ja) 2002-11-29 2004-06-17 Banyu Pharmaceutical Co., Ltd. 新規アゾール誘導体
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2004058264A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AR044283A1 (es) * 2003-05-19 2005-09-07 Merck & Co Inc Procedimeinto para preparar compuestos de espirolactona
WO2004110368A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US20070099884A1 (en) * 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
US20050069244A1 (en) * 2003-09-25 2005-03-31 Miguel Dajer Flexible distributed wireless signal system and method
WO2005030208A1 (en) * 2003-09-26 2005-04-07 Pfizer Products Inc. Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders
BRPI0414804A (pt) * 2003-09-26 2006-11-14 Pfizer Prod Inc tratamento de perturbações neurológicas relacionadas com perturbações de sono para movimentos oculares rápidos (rem) com antagonistas dos receptores npy y5
US20080255216A1 (en) 2004-03-29 2008-10-16 Aster Susan D Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
CA2575736A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2374455A3 (en) 2004-08-19 2012-03-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
WO2006022454A1 (ja) 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
DE602005014124D1 (de) * 2004-09-07 2009-06-04 Banyu Pharma Co Ltd Carbamoylsubstituiertes spiro-derivat
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
RU2007124373A (ru) 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
NZ556732A (en) 2005-01-25 2011-11-25 Synta Pharmaceuticals Corp Pyrazine compounds for inflammation and immune-related uses
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060270650A1 (en) * 2005-05-26 2006-11-30 Macneil Tanya Combination therapy for the treatment of obesity
AU2006253312B2 (en) 2005-05-30 2011-08-18 Msd K.K. Novel piperidine derivative
WO2007016028A2 (en) * 2005-07-28 2007-02-08 Merck & Co., Inc. Synthesis and crystalline forms of npy5 antagonist
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
CA2619770A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
US8193208B2 (en) * 2005-09-09 2012-06-05 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
CN101291662A (zh) 2005-10-21 2008-10-22 诺瓦提斯公司 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
US7858635B2 (en) * 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
RU2008137583A (ru) * 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейшн (Us) Спиропиперидины в качестве модуляторов мускариновых рецепторов
EP1988892A2 (en) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
SI2007752T1 (sl) 2006-03-31 2010-12-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
AU2007269863A1 (en) * 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2660903A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101573121A (zh) * 2006-08-18 2009-11-04 弗特克斯药品有限公司 毒蕈碱受体调节剂
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
BRPI0720004A2 (pt) 2006-12-07 2013-12-17 Hoffmann La Roche Derivados de espiro-piperidina como antagonista de receptor v1a
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
US7501432B2 (en) 2006-12-22 2009-03-10 Hoffman-La Roche Inc. Spiro-piperidine derivatives
RU2009123133A (ru) 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные спиро-пиперидина
CN101589046B (zh) * 2006-12-29 2011-09-21 弗·哈夫曼-拉罗切有限公司 氮杂螺环衍生物
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009045519A1 (en) * 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
MX2010005345A (es) * 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
JP2011505366A (ja) * 2007-11-30 2011-02-24 ワイス・エルエルシー ホスホエステラーゼ１０の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ［１，５−ａ］ピラジン
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
CN102014900B (zh) * 2008-03-11 2014-04-02 大学健康网络 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
CA2741839A1 (en) * 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
TW201111383A (en) 2009-05-29 2011-04-01 Wyeth Llc Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US8765728B2 (en) 2009-11-16 2014-07-01 Mellitech [1,5]-diazocin derivatives
JP5540454B2 (ja) 2009-12-30 2014-07-02 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ阻害剤
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
EP2579873A4 (en) 2010-06-11 2013-11-27 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
JP6471103B2 (ja) 2013-03-06 2019-02-13 ヤンセン ファーマシューティカ エヌ．ベー． ヒスタミンｈ４受容体のベンゾイミダゾール−２−イルピリミジンモジュレータ
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
US10076698B2 (en) 2016-05-17 2018-09-18 Sportsmedia Technology Corporation Automated or assisted umpiring of baseball game using computer vision
KR20190065312A (ko) 2016-10-14 2019-06-11 테스 파마 에스.알.엘. 알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
ES2255330T3 (es) * 1998-11-10 2006-06-16 MERCK & CO., INC. Espiroindolinas como antagonistas del receptor y5.

Also Published As

Publication number Publication date
US6388077B1 (en) 2002-05-14
IS6267A (is) 2002-02-13
CA2379103C (en) 2010-06-15
DE60006251D1 (de) 2003-12-04
TR200200408T2 (tr) 2002-06-21
SK286609B6 (sk) 2009-02-05
CA2379103A1 (en) 2001-03-01
DZ3175A1 (fr) 2001-03-01
CN1202108C (zh) 2005-05-18
HK1043123B (zh) 2004-01-30
NO323514B1 (no) 2007-06-04
IS2420B (is) 2008-10-15
EA004507B1 (ru) 2004-04-29
SK2522002A3 (en) 2002-08-06
TWI279402B (en) 2007-04-21
US6326375B1 (en) 2001-12-04
CN1640877A (zh) 2005-07-20
DE60006251T2 (de) 2004-05-13
NO20020814D0 (no) 2002-02-19
MY130769A (en) 2007-07-31
CN1370168A (zh) 2002-09-18
NO20020814L (no) 2002-04-15
AU767229B2 (en) 2003-11-06
WO2001014376A1 (en) 2001-03-01
PE20010645A1 (es) 2001-06-07
GEP20053488B (en) 2005-04-25
RS50484B (sr) 2010-03-02
EE05248B1 (et) 2009-12-15
EE200200082A (et) 2003-06-16
HUP0203107A2 (hu) 2002-12-28
KR20020021410A (ko) 2002-03-20
DK1204663T3 (da) 2004-02-09
PT1204663E (pt) 2004-02-27
CZ2002533A3 (cs) 2002-08-14
MXPA02001693A (es) 2002-08-06
BR0013423A (pt) 2002-05-07
HUP0203107A3 (en) 2004-06-28
HRP20020102B1 (en) 2005-04-30
CO5200768A1 (es) 2002-09-27
YU10802A (sh) 2004-09-03
PL353743A1 (en) 2003-12-01
HRP20020102A2 (en) 2004-02-29
NZ517057A (en) 2003-08-29
CN100457757C (zh) 2009-02-04
EP1204663A1 (en) 2002-05-15
ATE253064T1 (de) 2003-11-15
BG106390A (en) 2002-12-29
US20020052371A1 (en) 2002-05-02
AU6476200A (en) 2001-03-19
EP1204663B1 (en) 2003-10-29
KR100749713B1 (ko) 2007-08-16
EA200200270A1 (ru) 2002-08-29
BG65805B1 (bg) 2009-12-31
HK1043123A1 (en) 2002-09-06
US6335345B1 (en) 2002-01-01
WO2001014376A8 (en) 2001-08-09
AR029000A1 (es) 2003-06-04
ES2206287T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
HRP20020102B1 (en) Novel spiro compounds
EP1140083A4 (en) NEW CONNECTIONS
GB9902084D0 (en) Novel compounds
GB9902697D0 (en) Novel compounds
EG24063A (en) Novel compounds
GB9901256D0 (en) Novel compounds
GB9902070D0 (en) Novel compounds
GB9902880D0 (en) Novel compounds
GB9902937D0 (en) Novel compounds
GB9903278D0 (en) Novel compounds
GB9901209D0 (en) Novel compounds
GB9901946D0 (en) Novel compounds
GB9900162D0 (en) Novel compounds
GB9903414D0 (en) Novel compounds
GB9900090D0 (en) Novel compounds
GB9902936D0 (en) Novel compounds
GB9901462D0 (en) Novel compounds
GB0009267D0 (en) Novel compounds
GB9901903D0 (en) Novel compounds
GB9902657D0 (en) Novel compounds
GB9901602D0 (en) Novel compounds
GB9902879D0 (en) Novel compounds
GB9902169D0 (en) Novel compounds
GB9900959D0 (en) Novel compounds
GB9902078D0 (en) Novel compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees